Summary of findings table ‐ Recombinant activated factor VII vs placebo: Thromboembolic events
Recombinant human factor VII activated showed no clear difference in thromboembolic events by patients compared with placebo (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Recombinant human factor VII activated vs placebo Thromboembolic events by patients · patients with upper gastrointestinal bleeding and liver diseases. Recombinant human factor VII activated showed no clear difference in thromboembolic events by patients compared with placebo (moderate certainty). Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases (2012) · Cochrane Headline outcomes only | RR 0.8 [0.4, 1.6] | 2 studies · 507 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Human recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseases 2012 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.